These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 17404740)

  • 1. Comparison between a linear versus a macrocyclic contrast agent for whole body MR angiography in a clinical routine setting.
    Seeger A; Kramer U; Fenchel M; Grimm F; Bretschneider C; Döring J; Klumpp B; Tepe G; Rittig K; Seidensticker PR; Claussen CD; Miller S
    J Cardiovasc Magn Reson; 2008 Dec; 10(1):63. PubMed ID: 19116027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate Cancer Detection with Multiparametric MRI: A Comparison of 1 M-Concentration Gadobutrol with 0.5 M-Concentration Gadolinium-Based Contrast Agents.
    Hara T; Ogata T; Wada H; Yabuki T; Kanazawa S
    Curr Urol; 2018 Jun; 11(4):201-205. PubMed ID: 29997463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the hepatic tumor extracellular matrix using elastin-specific molecular magnetic resonance imaging in an experimental rabbit cancer model.
    Keller S; Borde T; Brangsch J; Reimann C; Kader A; Schulze D; Buchholz R; Kaufmann JO; Karst U; Schellenberger E; Hamm B; Makowski MR
    Sci Rep; 2020 Nov; 10(1):20785. PubMed ID: 33247185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic contrast-enhanced MR imaging of the prostate: intraindividual comparison of gadoterate meglumine and gadobutrol.
    Lee CH; Vellayappan B; Taupitz M; Hamm B; Asbach P
    Eur Radiol; 2019 Dec; 29(12):6982-6990. PubMed ID: 31264013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-dose 1.0-M gadobutrol versus standard-dose 0.5-M gadopentetate dimeglumine in revealing small hypervascular hepatocellular carcinomas.
    Kim YK; Lee YH; Kim CS; Han YM; Hwang SB
    Eur Radiol; 2008 Jan; 18(1):70-7. PubMed ID: 17404740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic contrast-enhanced magnetic resonance imaging evaluation of VX2 carcinoma in a rabbit model: comparison of 1.0-M gadobutrol and 0.5-M gadopentetate dimeglumine.
    Chang JM; Moon WK; Cha JH; Jung EJ; Cho N; Kim SJ
    Invest Radiol; 2010 Oct; 45(10):655-61. PubMed ID: 20808238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T.
    Attenberger UI; Runge VM; Jackson CB; Baumann S; Birkemeier K; Michaely HJ; Schoenberg SO; Reiser MF; Wintersperger BJ
    Invest Radiol; 2009 May; 44(5):251-6. PubMed ID: 19550376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.
    Liu D; Ma X; Liu J; Zhao L; Chen H; Xu L; Sun Z; Fan Z
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1191-1200. PubMed ID: 28289991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: intraindividual comparison with double-dose gadopentetate dimeglumine.
    Kim ES; Chang JH; Choi HS; Kim J; Lee SK
    AJNR Am J Neuroradiol; 2010 Jun; 31(6):1055-8. PubMed ID: 20110372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities.
    Kuwatsuru R; Takahashi S; Umeoka S; Sugihara R; Zeng M; Huan Y; Peng W; Ma L; Guo L; Teng G; Yao W; Tozaki M; Endo M; Kaji S; Ro T; Tae Hahn S; Chul Kang B; Nishimura H; Sugawara Y; Katakami N; Breuer J; Aitoku Y
    J Magn Reson Imaging; 2015 Feb; 41(2):404-13. PubMed ID: 24692302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma.
    Kim YK; Kim CS; Chung GH; Han YM; Lee SY; Chon SB; Lee JM
    AJR Am J Roentgenol; 2006 Jan; 186(1):149-57. PubMed ID: 16357395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraindividual comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine for time-resolved contrast-enhanced three-dimensional magnetic resonance angiography of the upper torso.
    Fink C; Puderbach M; Ley S; Risse F; Kuder TA; Bock M; Thaler J; Plathow C; Kauczor HU
    J Magn Reson Imaging; 2005 Aug; 22(2):286-90. PubMed ID: 16028246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced mr imaging.
    Kim YK; Kim CS; Kwak HS; Lee JM
    J Magn Reson Imaging; 2004 Nov; 20(5):826-37. PubMed ID: 15503325
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.